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Abstract
Currently, a major clinical challenge in the management 
of the increasing number of hepatitis C virus (HCV) 
infected patients is determining the best means for 
evaluating liver impairment. Prognosis and treatment 
of chronic hepatitis C (CHC) are partly dependent on 
the assessment of histological activity, namely cell 
necrosis and inflammation, and the degree of liver 
fibrosis. These parameters can be provided by liver 
biopsy; however, in addition to the risks related to an 
invasive procedure, liver biopsy has been associated 
with sampling error mostly due to suboptimal biopsy 
size. To avoid these pitfalls, several markers have 
been proposed as non-invasive alternatives for the 
diagnosis of liver damage. Distinct approaches among 
the currently available non-invasive methods are (1) 
the physical ones based on imaging techniques; and (2) 
the biological ones based on serum biomarkers. In this 
review, we discuss these approaches with special focus 
on currently available non-invasive serum markers. We 
will discuss: (1) class Ⅰ serum biomarkers individually 
and as combined panels, particularly those that mirror 
the metabolism of liver extracellular matrix turnover 
and/or fibrogenic cell changes; (2) class Ⅱ biomarkers 
that are indirect serum markers and are based on the 
evaluation of common functional alterations in the liver; 
and (3) biomarkers of liver cell death, since hepatocyte 
apoptosis plays a significant role in the pathogenesis of 
HCV infection. We highlight in this review the evidence 
behind the use of these markers and assess the 
diagnostic accuracy as well as advantages, limitations, 
and application in clinical practice of each test for 
predicting liver damage in CHC.
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2016 Hepatitis C Virus: Global view
TOPIC HIGHLIGHT
Core tip: Liver biopsy represents the gold standard 
for evaluating liver damage, but identification of 
non-invasive serum markers that mirror liver injury 
progression is the actual goal in both adults and 
children. Over the last few years, several non-invasive 
markers have been proposed, especially for liver fibrosis 
diagnosis. In this review, we discuss the role of serum 
biomarkers for predicting liver impairment in chronic 
hepatitis C patients. 
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Hepatitis related to hepatitis C virus (HCV) infection is 
a progressive disease that may result in chronic active 
hepatitis, cirrhosis, and hepatocellular carcinoma. It 
is estimated that about 160 million individuals, i.e., 
2.35% of the world population, are chronically infected 
with HCV[1,2]. The virus represents a major global 
health problem, since there is no available vaccine; 
and although there are recently approved direct-acting 
antiviral agents (DAA) available as well as more drugs 
in development, response to the current standards of 
care therapy (pegylated interferon-α and ribavirin) is 
limited. Furthermore, liver failure as a consequence of 
HCV infection is one of the most common reasons for 
liver transplantation[1].
The mechanisms leading to liver injury are under 
constant revision, but it is widely accepted that 
both immune system-mediated reactions and viral 
cytopathic effects are involved in the pathogenesis[3]. 
A major clinical challenge in the management of the 
increasing number of chronic hepatitis (CHC) infected 
patients is achieving the best means for evaluating liver 
impairment. The assessment of histological activity, 
namely cell necrosis and inflammation and the degree 
of liver fibrosis, have to date been provided by liver 
biopsy[2,4] (Table 1). The evaluation of the histological 
damage is considered crucial in the management of 
patients with CHC, because it provides prognostic 
information and, in many cases, assists in therapeutic 
decisions. While the evaluation of fibrosis is a major 
decision criterion for hepatologists, fibrosis is only one 
of the many histopathological features present on liver 
biopsy. In effect, fibrosis is not an independent trait, 
since scar tissue also results from other pathobiological 
mechanisms, such as inflammatory, degenerative, and 
dystrophical processes. The simultaneous evaluation 
of necroinflammation shows whether fibrosis is the 
result of a past event that has been stabilized or even 
regressed or is an ongoing process that may continue 
to worsen. Moreover, associated lesions, such as 
steatosis, steatohepatitis, iron overload, etc., which 
provide useful information for patient management 
and prognosis, can also frequently be detected within 
a biopsy[5]. Although the biopsy represents the gold 
standard for evaluating presence, type, and stage of 
liver fibrosis and for characterizing necroinflammation 
(portal tract inflammation, interface hepatitis, lobular 
inflammation); it remains a costly and invasive pro-
cedure with inherent risks. Minor complications are 
relative common, and about one fourth of patients 
have pain in the right upper quadrant or right shoulder 
after liver biopsy. The risk of severe complications 
is very low (1/4000-10000) and include significant 
bleeding rates, perforation of other organs, and 
death. Thus, it cannot be performed frequently for 
monitoring therapeutic outcomes[6-11]. Moreover, 
biopsy is considered risky in children since it carries a 
higher chance for the development of complications, 
consequently it is less accepted than adults. In 
addition to the risks related to an invasive procedure, 
liver biopsy has been associated with sampling 
error, mostly due to suboptimal biopsy size[12-14]. The 
sampling error constitutes a recognized drawback 
because the needle liver biopsy, regardless of the 
length or width of the core, is only a finite portion 
of a very large organ with potential variability in the 
expression of disease. Pathologists would certainly 
prefer larger samples to review, but comparative data 
now indicate that a non-fragmented specimen of at 
least 20 mm in length that includes at least 11 portal 
tracts would be a reliable specimen for disease grading 
and staging[15]. On the other hand, a fairly extensive 
literature concerning problems inherent in histological 
grading and staging systems has emerged. Histological 
features (necroinflammation = grading; fibrosis = 
staging) should be reported using a structured, semi-
quantitative method. Various scoring systems have 
been validated to evaluate liver damage in CHC. The 
most widely used scoring systems are METAVIR, 
Scheuer, Ishak, and Knodell’s hepatic activity index 
(HAI)[16,17]. METAVIR and Scheuer’s scores are more 
reproducible and less prone to observer variation 
but have less distinction capability both for fibrosis 
and necroinflammation than Ishak and Knodell’s 
HAI[17,18]. A further pitfall of biopsy examination is the 
interpreter, since there is a significant degree of inter-/
intra-observer variability in the pathologic assessment 
of liver samples. The practical knowledge and 
experience of the pathologist could greatly influence 
the interpretation of the diagnosis by improving 
consistency and accuracy and minimizing problems 
related to sample size[19]. Consequently, evaluation of 
liver damage by means of a biopsy will always carry a 
risk, albeit low, of misclassification, thus making the 
term ‘‘best” standard more appropriate than ‘‘gold” 
standard for liver biopsy. Therefore, developing non-
invasive tests that can accurately predict initial disease 
stage and progression over time represents a high 
priority and growing medical need[20,21]. Currently, 
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there are several non-invasive diagnostic methods for 
determining liver damage that are being validated, 
such as blood markers and imaging methods[22]. Over 
the last few years, several non-invasive markers 
were proposed, especially for liver fibrosis diagnosis. 
Besides the clear advantage of being non-invasive, 
a more objective interpretation of test results may 
overcome the mentioned intra- and inter-observer 
variability of liver biopsy. In addition, these tests can 
theoretically offer a more accurate view of fibrogenic 
events occurring in the entire liver, with the advantage 
of providing frequent fibrosis evaluation without 
additional risk. However, in general, these tests show 
low accuracy to discriminate among intermediate 
stages of fibrosis and may be influenced by several 
hepatic and extrahepatic conditions[23].
NON-INVASIVE METHODS FOR THE 
ASSESSMENT OF LIVER DAMAGE
There are two distinct approaches among the currently 
available non-invasive methods: (1) the physical ones 
based on imaging techniques; and (2) the biological 
ones based on serum biomarkers[24] (Figure 1). Although 
complementary, these two approaches are based on 
different rationales and conceptions. 
The physical approach 
Ultrasonography, doppler analysis, magnetic resonance 
imaging (MRI), computed tomography, transient 
elastography (TE), real time elastography, and acoustic 
radiation force impulse imaging are examples of 
imaging/scanning techniques. Of these, however, 
TE seems to be the most appropriate because it 
is fast, reproducible and not operator dependent. 
More specifically, TE measures liver stiffness in 
relation to elasticity, corresponding to a genuine and 
intrinsic physical property of the liver parenchyma. 
Several studies have shown a significant correlation 
between TE and fibrosis stage, as assessed by the 
METAVIR scoring system[25-27]. TE is a good predictor 
for severe fibrosis and is highly accuracy in the 
identification of liver cirrhosis [the area under the 
operating characteristic curves (AUROC) was ≥ 0.90 
in all reported studies][28]; however, a meta-analysis 
study indicated that TE examination alone does not 
provide sufficient information to diagnose significant 
fibrosis (F ≤ 2) and is unable to discriminate between 
intermediate stages of fibrosis[29]. Even though 
the TE examination per se is straight forward, the 
results must be interpreted by an expert clinician, 
knowledgeable about the clinical background of the 
patient and the conditions that can influence liver 
stiffness measurement. Risk factors for failure of 
liver stiffness measurement include obesity, narrow 
intercostal space, and ascites[28]. Since the liver 
is an organ wrapped in an expandable but non-
elastic envelope (Glisson’s capsula), additional space-
occupying tissue abnormalities independent of fibrosis, 
such as edema and inflammation, cholestasis and 
congestion, may interfere with TE. Acute viral hepatitis 
increases liver stiffness, so it may be a condition 
that can lead to a false positive on TE[30,31]. Thus, the 
necroinflammatory status needs to be taken into 
consideration, particularly in patients with absent or 
low-stage liver fibrosis. In patients with extra-hepatic 
cholestasis, liver stiffness significantly correlates with 
bilirubin levels and may lead to false positivity of TE 
measurement[23,32].
The biological approach 
The tremendous strides made in biomedicine and 
biotechnology during the last decade have led to 
novel, rapid, and non-invasive methods that challenge 
longstanding ‘‘gold standard’’ invasive diagnostic and 
therapeutic procedures. Any non-invasive method 
should ideally fulfill certain characteristics: it should 
be simple, accessible, easily interpretable, highly 
accurate, liver-specific, and satisfactorily validated[29]. 
Despite the aforementioned limitations of liver biopsy, 
there has been a clear resistance to accept non-
invasive diagnosis of liver fibrosis as a viable and 
preferable alternative to liver biopsy. The reasons 
are various: (1) there is a paucity of well-designed 
studies assessing non-invasive methods, and sufficient 
external validation for some of the proposed methods 
is lacking; (2) the number of proposed methods to 
assess disease severity remains in a state of constant 
growth, and there is practically no time to validate or 
test them all; (3) specific etiology-validation of the 
non-invasive methods should be provided considering 
that each etiology of chronic liver disease presents 
with specific pathogenesis, natural history, and 
associated comorbidities; (4) a careful evaluation of 
the risk factors for error and failure of a non-invasive 
tool should be carried out for adequate interpretation 
in clinical practice; and (5) liver biopsy itself is not 
an ideal gold standard to compare serum markers. 
Finally, and not least important, there is still significant 
opposition to changing what has long stood as dogma. 
The aforementioned reasons may explain why the 
introduction of non-invasive methods in clinical 
practice is making such slow headway in the field of 
hepatology. An exception to this rule is France, where 
three well-validated methods (FibroTest, Fibrometer, 
and FibroScan) have been approved by the public 
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Table 1  Advantages and disadvantages of liver biopsy
Liver biopsy
   “Gold” standard for evaluating liver damage 
   Provides prognostic information and assists in therapeutic decisions
   Invasive procedure with inherent risks
   Cannot be applied to monitor therapeutic outcomes 
   Sampling error mostly due to suboptimal biopsy size 
   Inter-/intra-observer variability 
   Costly 
   Less accepted in children than in adults
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(ECM) turnover and/or fibrogenic cell changes and can 
be utilized to assess the dynamics of liver fibrogenesis. 
The potential clinical usefulness of these markers is 
extremely interesting as they could be used not only 
to stage liver fibrosis but also to assess the rate and 
progression of liver fibrogenesis. This assessment, in 
turn, is translated into effective prognostic information 
and into a tool for evaluating the response and for 
monitoring the efficacy of antifibrotic drugs. However, 
the data available on their performance in defining 
the stage of liver fibrosis is variable. Moreover, they 
may not be routinely provided in every hospital 
setting, limiting their clinical use[29,33]. These markers 
include several glycoproteins (hyaluronan, laminin, 
etc.), members of the collagen family (procollagen Ⅲ, 
type Ⅳ collagen, and type Ⅳ collagen 7s domain), 
collagenases and their inhibitors (metalloproteinases 
and tissue inhibitors of metalloproteinases), and a 
number of cytokines involved in the fibrogenic process 
(in particular transforming growth factor (TGF)-β1). 
These have been analyzed individually as well as in 
combination to assess severity and progression of 
hepatic fibrosis and to follow up changes related to 
viral treatment[34-42].
Hyaluronic acid (HA) is the most studied direct 
health system and are routinely used in clinical 
practice[21]. Serum markers offer an attractive, cost 
effective alternative to liver biopsy for both patients 
and clinicians with a lot of advantages (substantially 
less invasive, practically no complications, little or no 
sampling errors, small observer related variability, and 
measurements may be performed repeatedly in any 
laboratory without sophisticated equipment, allowing 
for dynamic monitoring of fibrosis) and little limitation 
(low accuracy to discriminate between intermediate 
stages of fibrosis and the influence of several extra-
hepatic factors). Although no single ideal marker 
exists, several markers have been proposed as useful 
indicators of liver damage. The most commonly used 
markers are discussed below. 
DIRECT SERUM MARKERS 
(CLASS Ⅰ BIOMARKERS)
More recently, a better understanding of the path-
ophysiology of liver fibrosis has prompted many 
investigators to use more refined markers to identify 
different fibrosis stages. Class Ⅰ biomarkers are those 
that mirror the metabolism of liver extracellular matrix 
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Figure 1  Non-invasive methods for liver damage assessment.  
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serum marker. It is a glucosaminoglycan that is syn-
thesized and distributed throughout the extracellular 
space by hepatic stellate cells (HSCs). HA is degraded 
by hepatic sinusoidal endothelial cells[43]. Elevated 
serum HA levels have been associated with decreased 
hepatic removal of HA in the development of hepatic 
sinusoid capillarization, increased production of HA 
in the damaged liver, and increased extrahepatic 
production of HA during inflammation[44,45]. HA 
levels correlate with liver fibrosis and are particularly 
increased in cirrhosis in both patients mono-
infected with HCV and co-infected with HCV/human 
immunodeficiency virus (HIV)[39-42,45]. Moreover, HA 
serum levels have been strongly associated with 
advanced stages of liver fibrosis, with AUROC for 
significant fibrosis ranging from 0.73 to 0.86 and 
for advanced fibrosis from 0.92 to 0.97[36,39-42,46,47]. 
Furthermore, a cross-sectional study on 201 HCV/
HIV co-infected patients revealed that the diagnostic 
accuracy of serum HA is better than other non-
invasive indices like fibrosis-4 (FIB-4), aspartate 
aminotransferase (AST) platelet ratio index (APRI), 
and Forns[47]. Although data suggest that HA alone is 
clinically useful for predicting severe fibrosis, it has 
been demonstrated that the best results could be 
obtained when it is combined with other markers of 
liver fibrosis[34].
In the healthy human liver, the most abundant 
collagens are the fibril-forming types Ⅰ and Ⅲ. In its 
mature form, collagen is integrated into the ECM. 
Particularly, procollagen type Ⅲ amino-terminal 
peptide (PⅢNP) is a major constituent of the 
connective tissue. During fibrogenesis, the ratio of the 
type Ⅰ/Ⅲ changes from 1:1 in the healthy liver to 1:2 
in the cirrhotic liver[48]. The relative concentration of P
ⅢNP in the basement membrane is higher in hepatic 
fibrogenesis and is closely followed by an increase in 
its serum level[49]. In acute hepatitis, the serum level 
of PⅢNP correlates with aminotransferase levels, 
whereas in chronic liver disease serum PⅢNP reflects 
the stage of liver fibrosis[50], although the diagnostic 
value of PⅢNP shows discordant results. Leroy et al[36] 
described that the diagnostic accuracy of PⅢNP was 
better than that of HA, but the capability to distinguish 
F0/F1/F2 from F3/F4 was minimal, and the staging 
power of both markers was very similar (AUROC 0.88 
for PⅢNP and 0.81 for HA). Likewise, Zheng et al[51] 
reported that PⅢNP showed better accuracy than 
HA for the assessment of liver fibrosis, showing an 
AUROC of 0.80 and 0.72, respectively. In contrast, 
other authors described that the diagnostic value of P
ⅢNP seem to be lower than other markers, such as 
type Ⅳ collagen or HA[40,42,52]. Unfortunately, PⅢNP is 
not specific for liver fibrosis, since it is also elevated 
in acromegaly, lung fibrosis, chronic pancreatitis, and 
rheumatologic disease[48]. On the other hand, type Ⅳ 
collagen was also studied as a possible serum marker 
for the diagnosis of advanced fibrosis. However, the 
diagnostic value of type Ⅳ collagen assessment seems 
to be inferior to that of HA[29,40,52].
Laminin is a major non-collagenous glycoprotein 
synthesized by the HSC, which is deposited in the 
basement membrane of the liver. During fibrosis, 
laminin accumulates around the vessels, in the 
perisinusoidal spaces, and near the portal tract[53]. 
Elevated levels of laminin and pepsin resistant laminin 
(laminin P1) were found to correlate with the degree of 
perisinusoidal fibrosis[54]; however, the diagnostic value 
of laminin proved to be not as high as those of HA and 
type Ⅳ collagen[55,56]. 
It is well known that liver fibrosis is characterized 
by pathological accumulation of ECM, resulting 
from alterations of synthesis and/or degradation of 
matrix proteins. Matrix metalloproteinases (MMPs) 
constitute a family of zinc endopeptidases capable of 
degrading collagens. They play an important role in 
the physiologic processes of tissue remodeling, wound 
healing, and in several pathological states, including 
liver fibrosis[57]. As the activity of MMPs is regulated 
by specific tissue inhibitors of metalloproteinases 
(TIMPs), the imbalance between MMPs and TIMPs 
is thought to be an important determinant of ECM 
deposition and breakdown[36,58,59]. MMP-2 and tissue 
inhibitors of MMP-1 and -2 (TIMP-1 and -2) have some 
diagnostic potential for the detection of liver fibrosis in 
CHC patients[36,60]. TIMP-1 especially was thoroughly 
studied as a serum marker of liver damage; however, 
conflicting results were reported. Many authors found 
a link between TIMP-1 levels and fibrosis stage in 
adults[36], while others did not[42,61,62]. Nevertheless, 
the best results were obtained when TIMP-1 was 
combined or included in an algorithm together with 
other markers of liver fibrosis[34,38].
YKL-40 (chondrex) is a mammalian homologue 
of the bacterial chitinases involved in remodeling or 
degradation of the ECM[63]. In liver diseases, serum 
levels of YKL-40 correlate with fibrosis severity[50]. A 
study including 109 CHC patients showed a discrete 
performance for significant liver fibrosis (AUROC 0.81, 
specificity of 81% and sensitivity of 78%); and its 
accuracy for the prediction of liver cirrhosis was even 
lower (AUROC 0.80)[40].
During the development of liver fibrosis, multiple 
cytokines activate HSCs and transform them into 
myofibroblasts with new phenotypic properties, such 
as collagen synthesis and cytokine activation. TGF-β1 
is one of the multifunctional cytokines related to the 
production and degradation of ECM and the apoptosis 
of hepatic cells[58]. However, the relationship between 
TGF-β1, a pro-fibrogenic cytokine, and hepatic fibrosis 
is not well established. Nelson et al[64] stated that 
fibrogenesis is a long process and that the level of 
fibrosis was a summation of all the effects in the past; 
therefore, active TGF-β1 at a certain time point might 
not correlate with the fibrosis score. In a recent study, 
we described that serum TGF-β1 levels in CHC adult 
patients displayed an inverse relationship with fibrosis 
stage, where lower TGF-β1 values corresponded 
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to more severe fibrosis stages (AUROC 0.835)[42]. 
Moreover, the lowest levels of TGF-β1 were detected in 
serum samples from adult cirrhotic patients. Then, in 
accordance with other authors, lower levels of TGF-β1 
might indicate advanced liver fibrosis, suggesting 
that this marker may reflect fibrogenesis rather than 
fibrosis[65,66].
Direct markers have also been proposed as combined 
panels for increasing the diagnostic performance of a 
single parameter. 
The FIBROSpect Ⅱ test uses a combination of 
several components of the fibrogenic cascade, such 
as HA, TIMP-1, and α2-macroglobulin, to calculate a 
composite score. The test is intended to differentiate 
mild fibrosis (METAVIR stages F0 to F1) from more 
severe disease (METAVIR stages F2 to F4) and has 
been shown to do well in CHC cohorts[67]. FIBROSpect 
Ⅱ showed an AUROC of 0.82-0.87 for significant 
fibrosis[67-69].
Fibrometer® is a patented test combining age, 
platelets, HA, AST, prothrombin index, urea, and α2-
macroglobulin. In CHC patients, AUROC values were 
reported to be between 0.85-0.89 for significant liver 
fibrosis and 0.91 for liver cirrhosis[70-72]. In addition, direct 
comparisons showed that the Fibrometer® performed 
better than APRI and the FibroTest® in detecting both 
significant fibrosis and cirrhosis[73,74].
Hepascore® is another patented test that combines age, 
gender, HA, bilirubin, gamma glutamyl-transpeptidase 
(γGT), and α2-marcoglobulin. An interesting advantage 
of Hepascore® is that it can be totally automated 
using a single analyzer and only one serum sample[75]. 
In CHC patients, AUROC values of Hepascore® 
were 0.79-0.85 for diagnosis of significant fibrosis 
and 0.89-0.94 for diagnosis of cirrhosis, indicating an 
excellent performance[72,76,77]. 
The Original European Liver Fibrosis (OELF) panel 
proposed by the European liver fibrosis study group 
includes HA, TIMP-1, PⅢNP, and age. OELF was shown 
to be specific and sensitive in the evaluation of liver 
fibrosis in chronic liver disease of different etiology[21]. 
The European Liver Fibrosis (ELF) panel is a simplified 
version of the OELF that excludes the age variable[38]. 
ELF showed an AUROC range for significant fibrosis 
of 0.77-0.87 in the CHC patient and an AUROC of 
0.82-0.90 for cirrhosis[37,38,78]. 
The SHASTA Index, which consists of HA, AST, and 
albumin, was evaluated in a cohort of 95 patients with 
HIV/HCV co-infection[79]. This index showed an AUROC 
for significant fibrosis of 0.88, and this performance 
was significantly better than the APRI test in this HIV/
HCV cohort[50]. 
INDIRECT SERUM MARKERS (CLASS Ⅱ 
BIOMARKERS)
The first approach used to assess the degree of liver 
fibrosis by non-invasive means consisted of routine 
biochemical and/or hematological tests. These 
so-called class Ⅱ biomarkers are indirect serum 
markers and are based on the evaluation of common 
functional alterations in the liver, alterations that do 
not necessarily reflect ECM turnover and/or fibrogenic 
cell changes. These indirect markers are based 
mainly on a single or an algorithmic elaboration of 
commonly observed alterations in liver function (e.g., 
platelet count, AST, and total cholesterol). In general, 
assessment through indirect markers is, therefore, 
easy to obtain as it is based on laboratory tests 
already available in hospital general laboratories. The 
best known tests based on indirect markers include: 
AAR index (AST/alanine aminotransferase (ALT) 
ratio), APRI index (AST/platelet ratio)[80], the PGA 
(prothrombin index, γ-glutamyl-transpeptidase-GGT-, 
and apolipoprotein)[81], the PGAA (same as PGA plus 
α2-macroglobulin)[82], FIB-4 score (which combines 
platelet count, ALT, AST, and age), Forns index (age, 
platelet count, γGT, cholesterol)[83], and FibroTest (α2-
macroglobulin, haptoglobin, γGT, apolipoprotein A1, 
and bilirubin)[84,85]. 
Concerning AAR, although some studies have found 
promising results, its performance as a non-invasive 
marker of fibrosis is generally low, especially for the 
diagnosis of less advanced stages of fibrosis[86,87]. 
An AAR increase over 0.8 reflects a progressive liver 
functional impairment, while a ratio ≥ 1 is indicative 
of cirrhosis[88]. The diagnostic accuracy of ARR for 
distinguishing between cirrhotic patients and non-
cirrhotic ones in different studies is variable, with an 
AUROC of 0.51-0.83[29]. Moreover, the AAR had low 
performance for detecting significant fibrosis (AUROC 
of 0.661) as compared to other simpler models, such 
as APRI (AUROC 0.793) and FIB-4 (AUROC 0.811)[75].
The APRI is a useful tool to discern or exclude 
significant liver fibrosis (cut off 0.5-1.5) and liver 
cirrhosis (cut off 1-2). However, in a substantial 
number of patients (30%-50%), APRI values are 
within an intermediate area, and classification is 
unreliable. Nonetheless, to date, APRI remains one 
of the most validated non-invasive biomarkers for 
liver fibrosis, and it is among the most referenced 
by guidelines[10]. In the first study in which APRI 
was proposed, a high precision for the prediction 
of significant fibrosis (AUROC 0.88) and cirrhosis 
(AUROC 0.94) was demonstrated[80]. Subsequent 
studies indicated, however, an irregular performance 
with AUROC for significant fibrosis ranging between 
0.69-0.88 and for cirrhosis between 0.61-0.94[28,89]. 
This variability could be partially explained by the 
different cutoff values chosen in each study and by 
the population heterogeneity. A recent meta-analysis 
of 40 studies, which included 8739 patients with CHC, 
concluded that APRI can be used in clinical practice 
for the confirmation of severe fibrosis/cirrhosis when 
other clinical signs and examination are non-decisive 
(AUROC for the diagnosis of significant fibrosis, severe 
fibrosis, and cirrhosis were 0.77, 0.80, and 0.83, 
respectively)[90]. In this meta-analysis, the best cutoff 
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for diagnosing significant fibrosis was 0.7 while for the 
detection of cirrhosis it was 1.0. Since it is cheap and 
simple, it should be considered a reference test against 
which other non-invasive methods are compared. 
Therefore, APRI is still the first choice for CHC patients 
to identify fibrosis in regions with limited healthcare 
resources. A major advantage of APRI is that it was 
validated in special populations, such as individuals 
with HIV/HCV co-infection[90,91], in whom the overall 
performance seems to be lower than HCV mono-
infected individuals[90,92]. 
The PGA and PGAA index are very interesting 
since they implicate both inflammation and fibrosis in 
chronic liver diseases; however, their overall accuracy 
is relatively low to other indices[50]. 
The Forns index can be used to differentiate 
patients with mild (F0-F1) fibrosis from those with 
severe (F2-F4) fibrosis, but it shows less accuracy 
for distinguishing patients with stage F2 versus F4. 
However, several studies revealed a wide dispersion 
in the diagnostic performance of the Forns index 
for the detection of significant fibrosis (AUROC 
0.76-0.79)[72,83,89]. The major limitation of the Forns 
index is that it does not offer conclusive information 
regarding cirrhosis, while it leaves a high number of 
cases unclassified[75]. 
The FIB-4 was originally developed for HIV/HCV co-
infected patients, with cutoff values of 1.45 or 3.25 to 
rule-out or rule-in significant fibrosis, respectively[93]. 
This model was subsequently validated by Vallet-
Pichard et al[94] in a large cohort of HCV mono-infected 
patients. The FIB-4 index correctly identified patients 
with severe fibrosis (F3-F4) and cirrhosis with an 
AUROC of 0.85 and 0.91, respectively. A FIB-4 index 
< 1.45 had a negative predictive value of 94.7% to 
exclude severe fibrosis and a sensitivity of 74.3%. A 
FIB-4 index higher than 3.25 had a positive predictive 
value of 82.1% for the confirmation of significant 
fibrosis (F3-F4), with a specificity of 98.2%. Since the 
FIB-4 index is simple and inexpensive, it has been 
validated in a number of studies with a variable degree 
of accuracy in HCV infected subjects[95-97]. Amorim 
et al[98] compared FIB-4 and APRI and found similar 
AUROCs for both models (0.81 vs 0.79, respectively), 
but the proportion of biopsies that could have been 
correctly avoided was substantially higher with FIB-4 
than with APRI (63% vs 47%), suggesting that FIB-4 
is probably a more useful tool for incorporation into 
daily practice[98].
The FibroTest/FibroSure (identical tests but diffe-
rent names in Europe and America, respectively) 
and ActiTest are for the assessments of fibrosis and 
necroinflammatory activity. Their score is computed 
by accessing a proprietary website and entering the 
patient’s data (age, sex, haptoglobin, α2-macroglobulin, 
apolipoprotein A1, GGT, and bilirubin) and can only be 
performed in validated laboratories[99,100]. It generates 
a score that is correlated with the degree of liver 
damage in people with a variety of liver diseases. This 
test showed an AUROC range of 0.74-0.89 for the 
diagnosis of significant fibrosis and an AUROC range of 
0.82-0.92 for cirrhosis[21]. Among the patented panels 
combining parameters for diagnosis of liver fibrosis, 
FibroTest/Fibrosure is the most validated; however, 
it is important to note that risk factors leading to 
errors of this test include elevated bilirubin levels 
unrelated to fibrosis (for example due to cholestasis or 
Gilbert syndromes), reduction of haptoglobin related 
to hemolysis, and elevation of haptoglobin and α2-
macroglobulin due to non-hepatic inflammation[29]. 
In contrast to the numerous liver fibrosis biomarkers, 
only a few biomarkers of necroinflammatory histological 
activity have been published. ActiTest is a biomarker of 
liver necroinflammatory histological activity that was 
initially validated in patients with CHC[84,101] and then 
in patients with chronic hepatitis B (HBV)[85]. ActiTest 
is widely used in association with FibroTest as a non-
invasive alternative to liver biopsy[102]. It combines 
ALT and the five components of FibroTest. Poynard et 
al[102] assessed the accuracy of ActiTest in comparison 
with ALT in a meta-analysis of six studies including 
2017 patients and described that the accuracy of 
ActiTest for grading the necroinflammatory activity 
of patients with CHC is significantly higher than ALT 
serum activity alone. The overall accuracy of ActiTest 
for the diagnosis of any activity grade ranged between 
0.79-0.74. Notably, the non-invasive assessment 
of necroinflammatory grade combined with fibrosis 
stage is still crucial for at least three reasons: (1) for 
treatment prescription, which could be discussed in 
patients without advanced fibrosis but with moderate 
or severe necroinflammatory activity[1] and for 
maintenance therapy in patients with cirrhosis in order 
to reduce necrosis and inflammation[103,104]; (2) for the 
risk of false positives induced by necroinflammatory 
activity on fibrosis biomarkers[105] and on liver stiffness 
measurements by fibroscan[106,107]; and (3) for the risk 
of over interpretation of fibrosis improvement after 
antiviral treatment if the impact on necroinflammatory 
activity is not taken into account[102,105]. 
In addition to the combined panels that include 
different markers, many authors have proposed 
improving the accuracy of non-invasive methods for 
the correct diagnosis of liver damage in CHC using 
serum-based algorithms as a simultaneous or a 
sequential procedure. The use of two or more non-
invasive methods increases the diagnostic accuracy 
of an individual assay[72,89,108-110]. The choice of the 
algorithm to be used in the clinical practice may be 
based on some considerations: (1) what is locally 
available; (2) what has been recently validated; (3) 
what is not affected by patient co-morbidities; and (4) 
which method does the physician feel comfortable[29]. 
There are a large number of proposed algorithms that 
involve different markers; but we will only discuss the 
most widely applied. Sebastiani et al[111] investigated 
the viability of combining APRI and FibroTest/Fibrosure 
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[Sequential Algorithm for Fibrosis Evaluation (SAFE)] 
to identify significant fibrosis and cirrhosis in more 
than 2000 patients with CHC. This model uses APRI 
as a first line test because of its simplicity and low 
cost and FibroTest as a second line test because of 
its accuracy and higher cost. Importantly, the model 
uses liver biopsy as a third line test only in cases 
where the combined non-invasive biomarkers fail 
to classify with adequate accuracy. The algorithm 
used to identify significant fibrosis avoided 50% of 
liver biopsies, whereas an algorithm used to identify 
cirrhosis avoided more than 80% of biopsies. Castera 
et al[25] proposed the Bordeaux algorithm. They 
showed that the combination of TE and FibroTest 
was very useful for diagnosing significant fibrosis 
and cirrhosis, with AUROC measuring 0.88 and 0.95, 
respectively. Boursier et al[112] proposed a new fibrosis 
index that combined Fibrometer and TE. This index 
identifies patients with clinically significant/severe 
fibrosis with more accuracy than FibroTest, Fibrometer, 
or TE; avoiding 86% of liver biopsies. It is important 
to note that the combination of TE with serum-
based tests is currently a common modern practice. 
Calès et al[113] described a new test called Elasto-
Fibrometer (E-Fibrometer that includes all eight single 
components of Fibrometer and Fibroscan, resulting in 
a binary logistic regression targeted to F ≥ 2 or F4. 
E-Fibrometer provides higher accuracy than the other 
tests with AUROCs at 0.848 for F ≥ 2 and 0.926 for 
F4. 
Another proposed stepwise algorithm combines 
Hepascore® with APRI named Bourliere’s algorithm[114]. 
This approach yielded 91% diagnostic accuracy and 
reduced liver biopsies for significant fibrosis by 45%. 
To date, its main drawback is the lack of extensive 
validation data for Hepascore®, as compared to APRI, 
FibroTest, and Forns index. Moreover, Bourliere et al[108] 
proposed another combination algorithm consisting 
of Forns index, FibroTest, and APRI that showed good 
performance for diagnosing both significant fibrosis 
and cirrhosis, saving around 50% and 80% of liver 
biopsies, respectively. Moreover, Leroy et al[72] proposed 
another combination algorithm using FibroTest and 
APRI in concordance, which demonstrated exceptional 
performance in the diagnosing of significant fibrosis. 
BIOMARKERS OF LIVER CELL DEATH
Based on the morphological characteristics of liver 
biopsies, it is currently accepted that hepatocyte 
damage is a result, at least in part, of apoptosis 
induction. Both in vitro studies and in vivo models 
have demonstrated the induction of apoptosis by 
HCV[3,115-117]. Furthermore, some studies including 
adult patients indicated that hepatocyte apoptosis 
plays a significant role in the pathogenesis of HCV 
infection[116,118-123]. Non-invasive biomarkers of cell 
death are evolving as promising tools to diagnose and 
monitor liver damage in various acute and chronic liver 
diseases. The understanding and identification of key 
molecules involved in biochemical cascades leading 
to cell death in liver pathophysiology have offered 
new options for the development and testing of novel 
serum markers of liver damage[124]. Unfortunately, 
although there are many studies that evaluate these 
serum apoptosis markers in CHC patients related to 
liver damage, the study of the diagnostic accuracy of 
these markers for the diagnosis of liver injury severity 
is lacking. 
The cellular content of the soluble fraction of 
cytokeratin-18 (CK18), the major intermediate 
filament protein in the liver, has been shown to be 
released into the extracellular space during cell death 
both in vitro and in vivo. CK18 is cleaved by caspases 
at two conserved residues during apoptosis, one of 
them (Asp 396) represents a neoepitope (M30), which 
is not detectable in vital or necrotic cells. Circulating 
levels of M30 have been shown to be elevated in 
various other liver disorders, but it was particularly 
studied for the diagnosis of nonalcoholic steatohepatitis 
(NASH) among patients with nonalcoholic fatty liver 
disease (NAFLD)[125]. However, Bantel et al[119,126-128] 
extensively studied hepatocyte cell death and the 
release of M30 in patients with CHC. They found that 
serum M30 quantification is a highly sensitive method 
to detect early fibrosis severity[126]. They observed that 
M30 levels were associated with more severe stages 
of fibrosis only in patients with normal transaminase 
values, but no association between M30 and either 
hepatitis or fibrosis severity in general adult CHC 
patients was found. On the other hand, Seidel et 
al[129] found that M30 was elevated in adult patients 
with severe steatosis. Finally, Papatheodoridis et 
al[130] found that M30 was associated with global liver 
damage severity, because its levels correlated with 
hepatitis severity, fibrosis, and steatosis. Jazwinski et 
al[131] found elevated M30 levels in CHC patients when 
compared to controls, and while the stage of fibrosis 
was associated with increasing serum CK18 levels, 
there was no association between M30 and the grade 
of steatosis. In contrast, Joka et al[132] described that 
M65, another epitope that is present in both caspase-
cleaved and uncleaved CK-18, was more sensitive 
and specific than M30 for the detection of lower 
fibrosis stages and steatosis severity in many forms 
of chronic liver disease, including CHC; although M65 
and M30 were not individually analyzed in the context 
of each disease etiology. Moreover, in a previous 
study, we described that while M30 showed a trend of 
association with advanced fibrosis, it did not correlate 
with steatosis severity in adult patients[133]. Finally, 
while these studies support the association of CHC 
with increased circulating levels of M30, the potential 
clinical role and utility of these biomarkers in patients 
with CHC remains uncertain. 
Fas receptor/Fas ligand interaction is the primary 
initiator of the extrinsic apoptosis pathway in the 
liver. Therefore, the elimination of apoptotic bodies in 
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pathological conditions may induce an inflammatory 
reaction with consequent activation of HSCs, which 
in turn favors the development of liver fibrosis[134]. 
Several authors postulated that soluble Fas receptor 
(sFas) is associated with liver damage severity because 
significantly increased sFas levels were observed in 
patients with terminal disease stages, such as cirrhosis 
and hepatocellular carcinoma[135,136]. In turn, Toyoda 
et al[137] reported that sFas levels in CHC patients 
correlated with hepatitis severity. Kakiuchi et al[138] 
corroborated this result, but reported that this marker 
was not associated with fibrosis severity. In contrast, 
our previous study indicated that sFas was not related 
to hepatitis severity but instead was associated with 
fibrosis severity[133]. It follows then that serum sFas 
levels are high in patients with CHC; however, the 
clinical relevance of circulating sFas is not completely 
understood[135,138-143]. 
Tumor necrosis factor-alpha (TNF-α) is a pleiotropic 
monocyte derived cytokine that has been associated 
with cancer progression, severe inflammatory diseases, 
and liver injury[144]. In order to fulfill inflammatory 
reactions in the tissue, TNF-α binds to two distinct 
receptors: TNFR1 and TNFR2. Plasma TNF-α levels 
were significantly higher in patients with CHC, liver 
cirrhosis, and hepatocellular carcinoma compared 
to those with acute or mild CHC. Moreover, positive 
correlations between disease progression and soluble 
TNFR1 and soluble TNFR2 were described in patients 
with CHC[124].
SERUM MARKERS IN PEDIATRIC 
PATIENTS
HCV infection in adult patients has been explored 
so far; however, the natural history of HCV infection 
acquired in infancy and childhood remains poorly 
characterized, and the long-term outcome of the 
disease is still a matter of debate[145]. The spread of 
HCV infection in childhood is much more limited, but 
vertical transmission, in spite of its low efficiency, 
contributes to the maintenance of a reservoir of 
infection. Most children are asymptomatic with mildly 
abnormal hepatic transaminases[145-148]. Nevertheless, 
the full spectrum of elementary histological lesions 
described in adult patients can be observed in 
the liver of children and adolescents, including 
the typical triad of HCV-associated lesions; i.e., 
steatosis, portal aggregates of mononuclear cells, 
and bile duct damage. The prevalence of both portal 
lymphoid aggregates and bile duct injury seems to 
be significantly higher among older children[145,149,150]. 
Whether or not this ‘‘adult phenotype’’ of hepatitis 
C is related to the host’s immunoreaction remains 
speculative. In comparison with adults, children 
more often exhibit a mild disease activity. Septal 
fibrosis is not rare, but cirrhosis hardly ever develops 
during childhood. Liver fibrosis increases with the 
patient’s age and/or the duration of disease, so older 
adolescents and young adults have more severe 
fibrosis than children[150-152]. The progression of fibrosis 
is time dependent, even though it is a slow and non-
linear process. As mentioned above, biopsy in children 
is still perceived to carry a higher risk of complications, 
so it is less accepted than in adults. However, none 
of the several non-invasive tests proposed as an 
alternative to liver biopsy for grading and staging 
CHC have been investigated and/or validated in the 
pediatric population, so little is known about these 
tools in children. 
In a recent study of a cohort of pediatric patients 
with CHC, we evaluated the presence of a pro-
fibrogenic cytokine (TGF-β1) and certain matrix 
deposition markers (HA, PⅢNP, and TIMP-1) and then 
correlated them with liver injury. TGF-β1, TIMP-1, HA, 
and PⅢNP levels were higher in CHC patients than 
in age matched controls. Concerning liver damage, 
serum TGF-β1, PⅢNP, and HA showed no statistically 
significant differences among fibrosis stages; however, 
higher values of TIMP-1 were observed in pediatric 
patients with more severe fibrosis stages. Indeed, 
its accuracy for discriminating significant fibrosis was 
lower than that for discriminating advanced fibrosis 
(AUROC of 0.625 and 0.800, respectively)[42]. This 
observation is in agreement with data reported by 
Lebensztejn et al[153] on pediatric HBV patients. It is 
worthwhile to note that the highest TIMP-1 values 
were cirrhosis cases, so it would be interesting to 
analyze more cases from this condition to assess the 
actual diagnostic accuracy for cirrhosis. Finally, we 
compared the TIMP-1 result with APRI and AAR as 
surrogate indirect serum markers of liver fibrosis; but 
these approaches in our cohort did not improve the 
diagnostic accuracy performance of TIMP-1. In the 
pediatric series, neither APRI nor AAR reached the 0.80 
AUROC value, and TIMP-1 remained the best option[42].
FibroTest and ActiTest are potential non-invasive 
methods for assessing hepatic fibrosis and necro-
inflammatory activity in pediatric CHC patients. Since 
they observed AUROC of 0.97 when diagnosing patients 
with mild stage of fibrosis. these tests could discriminate 
them from those cases with no (or minimal) fibrosis. 
AUROC of 0.93 was useful to successfully discriminate 
between patients with moderate activity and those with 
mild activity[154,155]. 
Moreover, considering that HCV, apoptosis, and 
immune responses are all involved in CHC pathoge-
nesis in both pediatric and adult groups[123], we have 
recently evaluated the presence of different apoptosis 
markers and analyzed their correlation with liver 
injury in a cohort of CHC pediatric patients[133]. In 
particular, we measured sFas and M30 and found 
that sFas was associated with fibrosis severity (both 
significant and advanced fibrosis) and that M30 
levels were elevated in pediatric patients with severe 
steatosis. The diagnostic accuracy was good for sFas 
to evaluate advanced fibrosis (AUROC: 0.812) and 
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for M30 to determine steatosis severity in children 
(AUROC: 0.833). Serum sFas could be considered a 
possible marker of advanced fibrosis both in pediatric 
and adult patients with CHC, and M30 might be a 
good predictor of steatosis severity in children. This 
last finding is particularly important since M30 is being 
widely studied as a marker of steatosis severity both in 
pediatric and adult patients with NASH[156-162]. However, 
it would be useful to study larger pediatric cohorts, 
perhaps in a multicenter study, to validate and confirm 
these findings. Consequently, this approach would be 
potentially translatable to the bedside.
CONCLUSION
The accurate diagnosis of liver damage is essential for 
decision-making in CHC. Liver biopsy has traditionally 
been considered the gold standard for the evaluation 
of tissue damage, as it provides useful information for 
patient management and prognosis. However, it is an 
invasive procedure with a risk of potential complications 
and is prone to sampling errors. Even though in the 
last decade remarkable achievements have been 
made in the non-invasive diagnosis of liver damage, 
it is an evolving field, and there is still room for 
improvement. A number of non-invasive techniques, 
ranging from serum biomarker assays to advanced 
imaging techniques, are being developed. In general, 
these tests show low accuracy in discriminating among 
intermediate stages of fibrosis and may be influenced 
by several hepatic and extrahepatic conditions. In 
order to improve the accuracy of non-invasive methods 
to achieve the correct diagnosis of liver damage in 
CHC, algorithms combining different markers as well 
as the use of two or more non-invasive methods either 
simultaneously or in a sequential procedure have been 
proposed. Continued research in this area will give us 
the opportunity to offer our patients more precise and 
non-invasive diagnostic tools. Further research on the 
pathophysiology of CHC may identify novel markers 
that are able to accurately detect both progression 
and regression of liver damage. Liver biopsy will still 
be part of clinical practice in the coming years, but 
progress in biomedicine will challenge previously 
entrenched assumptions and will change our current 
approach to liver diseases in the next decade. 
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